On the occasion of the publication of its quarterly results, Merck announces that it has raised and tightened its target ranges for adjusted EPS and revenues for the full year 2024, expecting them from $8.53 to $8.65 and from $63.1 to $64.3 billion respectively.

For the first three months of the year, the pharmaceutical company posted non-GAAP EPS up 48% to $2.07, on sales of close to $15.8 billion, up 9% (+12% excluding currency effects).

Merck highlights continued strong revenue growth in oncology and vaccines, with currency-adjusted increases of 24% for its blockbuster Keytruda and 17% for its Gardasil/Gardasil 9 franchise.

Copyright (c) 2024 CercleFinance.com. All rights reserved.